Every 8-K that PARKERVISION INC (PRKR) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow PRKR and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full PRKR filings page.
ParkerVision, Inc. reported financial results for the quarter and six months ended June 30, 2026 and provided an update on ongoing patent litigation. Oral argument in its Federal Circuit appeal in ParkerVision v. Qualcomm was held on June 1, 2026, and the appellate decision remains pending. The company also noted expected revised scheduling orders in its western district of Texas cases following Judge Albright’s planned retirement.
For the three months ended June 30, 2026, ParkerVision recorded net income of $148 thousand, compared with a net loss of $1,634 thousand a year earlier, with no licensing revenue and a $1,723 thousand gain from the change in fair value of contingent payment obligations. Six‑month net loss narrowed to $1,405 thousand from $5,433 thousand. Cash and cash equivalents were $2,501 thousand at June 30, 2026, down from $4,360 thousand at December 31, 2025, after $1,737 thousand of net cash used in operating activities in the first half of 2026. Contingent payment obligations totaled $44,763 thousand, and shareholders’ deficit was $44,610 thousand.
ParkerVision, Inc. reported a planned change on its board of directors. On May 15, 2026, longtime director Lewis Titterton retired and resigned from the Board and from the Audit and Compensation Committees, with the company stating his departure was not due to any disagreement over operations, policies, or practices.
On May 19, 2026, the Board unanimously appointed Anthony (Tony) Bowers, age 69, as a Class II director to fill the vacancy and named him to the Audit and Compensation Committees. Bowers is Director of Corporate Sales at Intro-act, LLC and has over 30 years of corporate and institutional sales experience, including leadership roles at OTR Global and Goldman Sachs, and holds degrees from the Wharton School and Amherst College.
The company notes there are no special arrangements under which Bowers was selected, and no related-party transactions requiring disclosure. He will receive ParkerVision’s standard non-employee director compensation and has signed the company’s standard indemnification agreement. A press release announcing these changes was furnished as an exhibit.
ParkerVision, Inc. reported results for the three months ended March 31, 2026. Licensing revenue was $0 and net loss was $1.553 million, compared with a net loss of $3.799 million a year earlier, or $0.01 per share versus $0.03 per share.
Cash and cash equivalents were $3.423 million as of March 31, 2026, down from $4.360 million at year-end 2025. The balance sheet shows contingent payment obligations of $46.486 million and shareholders’ deficit of $45.524 million.
The company highlighted legal developments, including the Court of Appeals for the Federal Circuit granting an expedited schedule in its appeal in ParkerVision v. Qualcomm, with oral arguments set for June 1, 2026, and noted ongoing patent cases in Texas.
ParkerVision, Inc. disclosed that its Compensation Committee approved changes to outstanding nonqualified stock options held by CEO Jeffrey Parker and CFO Cynthia French. The company extended the options’ expiration date from August 7, 2026 to August 7, 2029 to maintain their long-term incentive value.
The modified awards cover 2,660,000 options for Mr. Parker and 870,550 options for Ms. French, all originally granted on August 7, 2019 with an exercise price of $0.171 per share. These options were fully vested as of the modification date.
ParkerVision expects to record a one-time, non-cash share-based compensation charge of approximately $360,000 related to this modification. Only the expiration dates were changed; the exercise price, number of shares, vesting status, and all other terms remained the same, and no additional securities were issued.
ParkerVision, Inc. reported a 2025 net loss of $7.4M, an improvement from a $14.5M loss in 2024, mainly due to a $0.6M gain from revaluing contingent payment obligations versus a $9.6M loss in 2024. Licensing revenue remained at zero and selling, general and administrative expenses rose to $7.6M from $4.3M, driven partly by a $3.0M increase in share-based compensation, including a one-time $2.5M noncash option modification charge.
Cash and cash equivalents were $4.4M at December 31, 2025, with net cash used in operations of $5.1M. The company raised approximately $4.5M in November 2025 through a registered direct sale of 21.2M shares at $0.21 per share and in March 2026 issued 3.2M shares at $0.21 per share to settle $0.67M of upcoming convertible note maturities.
On the legal front, the Court of Appeals for the Federal Circuit granted an expedited schedule in the Qualcomm appeal, with briefing completed by March 23, 2026 and oral argument to follow. A planned jury trial against MediaTek in Waco, Texas was postponed after the judge requested further support for the company’s damages expert, with a new schedule to be set after updated reports and briefings.
ParkerVision, Inc. entered into exchange agreements with certain holders of its convertible promissory notes. The holders agreed to swap the notes’ outstanding principal and accrued interest for common stock at an exchange price of $0.21 per share under a Section 3(a)(9) registration exemption.
The company issued 3,277,099 shares of common stock to these holders in exchange for the cancellation of notes with an aggregate outstanding principal amount of $675,000 and accrued and unpaid interest of approximately $13,200. The exchanged notes were cancelled and are no longer outstanding, reducing this portion of ParkerVision’s debt.
ParkerVision, Inc. reported new compensation awards for its top executives. On January 22, 2026, the board’s compensation committee granted performance-based stock options under the 2019 Long-Term Incentive Plan, including an option to purchase up to 8,000,000 shares for CEO Jeffrey Parker and an option to purchase up to 500,000 shares for CFO Cynthia French.
The options have a five-year performance period with quarterly measurement dates, a ten-year term, and an exercise price of $0.24 per share, based on the last sale price on the grant date. Vesting depends on cumulative net cash the company receives from its patent enforcement actions after specified fees and repayments.
These performance options fully vest automatically if the company’s market capitalization reaches at least $1 billion for 20 consecutive trading days or upon a change in control. The committee also granted the CFO a separate time-based option for up to 500,000 shares at $0.24 per share, vesting in four equal biannual installments over two years beginning July 22, 2026, and approved a 2.5% cost-of-living increase in the base salaries of the CEO and CFO effective April 15, 2026.
ParkerVision, Inc. (PRKR) reported that on November 24, 2025 it completed an offering and sale of 16,481,579 shares of common stock to accredited investors for an aggregate purchase price of $3,461,132. The shares were issued under the company’s existing shelf registration statement on Form S-3 and a prospectus supplement containing the final terms of the offering.
The company conducted this transaction directly, engaging no underwriters, placement agents, brokers, or finders and paying no commissions or fees, so the full purchase price goes to ParkerVision. The company also disclosed that it issued a press release announcing the closing of the transaction, which is included as an exhibit.
ParkerVision, Inc. entered into subscription agreements with accredited investors to sell 16,481,579 shares of common stock at $0.21 per share, for aggregate gross proceeds of approximately $3,461,132. The transaction is structured as a registered direct offering made by the company without an underwriter or placement agent.
The shares are being offered under ParkerVision’s existing shelf registration statement on Form S-3, and closing is expected to occur on November 24, 2025. Legal opinions and the form of subscription agreement are being filed as exhibits to support the issuance and sale of the securities.
ParkerVision, Inc. (PRKR) completed a registered offering of 4,761,905 shares of common stock for total proceeds of $1,000,000. The shares were sold on November 17, 2025 to company director Lewis H. Titterton, Jr. at $0.21 per share, matching the last reported sale price of the stock on the OTCQB Venture Market on November 14, 2025, under a subscription agreement dated that day. The issuance was made from ParkerVision’s Form S-3 shelf registration statement and a prospectus supplement that set the final terms. The company did not use underwriters or placement agents and paid no commissions or fees in connection with this transaction.
ParkerVision, Inc. entered into a subscription agreement for 4,761,905 shares of its common stock with director Lewis H. Titterton, Jr. for a total of $1,000,000. The shares are priced at $0.21 per share, matching the last reported sale price of the stock on the OTCQB Venture Market on November 14, 2025. The transaction is being conducted directly by the company without an underwriter, under an existing Form S-3 shelf registration. Because the buyer is a board member, the deal was reviewed and approved by disinterested directors under Florida corporate law, with closing expected on or before November 18, 2025.
ParkerVision, Inc. furnished an 8-K announcing it issued a press release reporting financial and operating results for the three and nine months ended September 30, 2025. The press release is attached as Exhibit 99.1 and incorporated by reference.
The company states the information, including Exhibit 99.1, is “furnished” and not “filed” under the Exchange Act, and will not be incorporated into Securities Act filings unless specifically referenced.